Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY10 | O00398 | 11/20 | 0.75 |
| ▸ | GPR34 | Q9UPC5 | 7/20 | 0.75 |
| ▸ | GPR174 | Q9BXC1 | 7/20 | 0.75 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.71 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.71 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | FABP3 | P05413 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22532171 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL21795574 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL20767229 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22498713 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531350 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| Phosphatidyl Serine SCHEMBL24802704 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532168 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22531357 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL22532089 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 | |
| SCHEMBL237694 | 1.00 | P2RY10 (0.75) | P2RY10GPR34GPR174LPAR3LPAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622979-B2 | Lipid nanoparticle used for delivering nucleic acid to brain tissue | NOF CORPORATION (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF CORPORATION (JP) | 2026-04-30 | — | — | US | disclosed |
| US-20250197852-A1 | LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS | NOF CORPORATION (JP) | 2025-06-19 | — | — | US | disclosed |
| EP-4501360-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | NOF Corporation (JP) | 2025-02-05 | — | — | EP | disclosed |
| US-20240408230-A1 | LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUE | NOF CORPORATION (JP) | 2024-12-12 | — | — | US | disclosed |
| CN-118973614-A | Lipid nanoparticles for delivery of nucleic acids to spleen tissue and methods of using the same for delivery of nucleic acids to spleen tissue | 日油株式会社 | 2024-11-15 | — | — | CN | disclosed |
| EP-4410275-A1 | LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUE | NOF Corporation (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4410276-A1 | LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS | NOF Corporation (JP) | 2024-08-07 | — | — | EP | disclosed |
| EP-4395820-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2024-07-10 | — | — | EP | disclosed |
| CN-118284407-A | Lipid nanoparticles for delivery of nucleic acids to brain tissue | 日油株式会社 | 2024-07-02 | — | — | CN | disclosed |
| CN-118251212-A | Lipid nanoparticles for delivery of nucleic acids to lymphatic endothelial cells | 日油株式会社 | 2024-06-25 | — | — | CN | disclosed |
| CN-117940158-A | Novel lipid nanoparticles comprising phosphatidylserine for nucleic acid delivery | 库瑞瓦格欧洲公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2023190176-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | 日油株式会社 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023054241-A1 | LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUE | 日油株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023054242-A1 | LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS | 日油株式会社 | 2023-04-06 | — | — | WO | disclosed |
| WO-2023031392-A2 | NOVEL LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS COMPRISING PHOSPHATIDYLSERINE | CureVac SE (DE) | 2023-03-09 | — | — | WO | disclosed |
| US-20220193108-A1 | Immunotherapeutic Nanoparticles And Methods Relating Thereto | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2022-06-23 | — | — | US | disclosed |
| WO-2020210317-A1 | IMMUNOTHERAPEUTIC NANOPARTICLES AND METHODS RELATING THERETO | WAKE FOREST UNIVERSITY HEALTH SCIENCES (US) | 2020-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115316-A1 | LIPID NANOPARTICLES FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE, AND METHOD FOR DELIVERING NUCLEIC ACID TO SPLENIC TISSUE USING SAME | SREBF1, SREBF2, FABP1 | P2RY10 4842/4885GPR34 3787/4885GPR174 3668/4885 |
| US-20250197852-A1 | LIPID NANOPARTICLES USED TO TRANSPORT NUCLEIC ACIDS INTO LYMPHATIC ENDOTHELIUM CELLS | LIPG, NPC1L1, FLT1 | P2RY10 4656/4885GPR34 3551/4885GPR174 1561/4885 |
| US-20240408230-A1 | LIPID NANOPARTICLE USED FOR DELIVERING NUCLEIC ACID TO BRAIN TISSUE | PHOSPHO1, FABP7, SGMS1 | P2RY10 4712/4885GPR34 4397/4885GPR174 2791/4885 |
| US-12622979-B2 | Lipid nanoparticle used for delivering nucleic acid to brain tissue | FABP7, SREBF1, SREBF2 | P2RY10 4869/4885GPR34 3763/4885GPR174 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.